SP0172 Glucocorticoids: Still a threat to bone?. (23rd January 2014)

• Record Type: Journal Article
• Authors: Compston, J.
• Is Part Of: Annals of the rheumatic diseases. Volume 71(2012)Supplement 3
• Page Start: 42
• Page End: 42
• Publication Date: 2014-01-23
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2012-eular.1647
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Osteoporosis is a common complication of oral glucocorticoid therapy and is associated with significant morbidity. Glucocorticoid-induced osteoporosis is characterised by rapid bone loss and increased fracture risk during the first few months of therapy. The increase in fracture risk is dose-related and is most prominent in the spine. Although awareness of glucocorticoid-induced osteoporosis has increased in recent years, the condition remains under-treated. Recently there have been advances in fracture risk assessment and treatment in glucocorticoid-induced osteoporosis. The fracture risk algorithm FRAX® includes glucocorticoid use as a risk factor but does not take account of the dose, thus underestimating fracture risk in individuals taking higher doses. A modification to FRAX has recently been developed that provides an adjustment for the dose of glucocorticoids. A range of pharmacological interventions is now available for the management of glucocorticoid-induced osteoporosis, including oral and intravenous bisphosphonates and the anabolic agent, teriparatide. New recommendations incorporating these advances have recently been issued by the American College of Rheumatology and a joint working group from the International Osteoporosis Foundation and the European Calcified Tissue Society. Disclosure of Interest: None Declared